Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease

doi:10.19803/j.1672-8629.20220559

Abstract

Abstract: Objective To explore the age of onset and stability of a KKAY animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease. Methods Eighteen twelve-week-old C57BL/6J mice were assigned to the control group that was fed with normal diets while another 18 twelve-week-old KKAy mice served as the model group that was fed with high-fat diets. Six mice in control and model group were randomly killed at the 14,18,22 weeks of age, respectively. Blood glucose, weight, serum liver function and lipid levels were monitored and the pathological changes of hepatic tissues were observed. Results Compared with the control group, the body mass, liver mass, liver index and blood glucose level of the model group increased significantly (P< 0.05) from the 14th week. The results of serology showed that the ALT, AST, CHOL, HDL-C and LDL-C levels were significantly increased compared with the control group (P< 0.05), but no significant difference was found in TG levels between the two groups (P> 0.05). Pathological staining showed both steatosis of hepatocytes in the 14th week and inflammatory cell infiltration in the 22nd week. Conclusion The 14-week-old KKAy mice treated with high fat diets can serve as a stable mouse model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease.

Key words: type 2 diabetes mellitus, nonalcoholic fatty liver disease, KKAy mice, animal model

CLC Number:

R965.1

WANG Shan, HUANG Jukai, WU Honghui, WEN Yalu, ZHANG Li, WANG Jianhua, YANG Xiaohui. Evaluation of a KKAy animal model of type 2 diabetes mellitus combined with nonalcoholic fatty liver disease[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 273-276.

References

[1] HAZLEHURST JM, WOODS C, MARJOT T, et al.Non-alcoholic fatty liver disease and diabetes[J]. Metabolism, 2016, 65(8): 1096-1108.
[2] RHEE EJ.Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective[J]. Endocrinol Metab (Seoul), 2019, 34(3): 226-233.
[3] DEWIDAR B, KAHL S, PAFILI K, et al.Metabolic liver disease in diabetes - From mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299.
[4] LEI L, HUAN Y, SUN SJ, et al.Novel specific peroxisome proliferator-activated receptorγ modulator YR4-42 corrects metabolic abnormalities and nonalcoholic fatty liver in type 2 diabetic KKAy mice[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(11): 1544-1548.
[5] ZHU HW, LI H, HAO F, et al.Liraglutide may reduce lipid metabolism in mice with type 2 diabetes and non-alcoholic fatty liver through AMPK pathway[J].Diabetes New World(糖尿病新世界), 2021, 24(18): 50-52,56.
[6] YI Q.Experimental study of rhodiola crenulata extract on NAFL and exploration of NASH mouse model[D]. Beijing: Peking Union Medical College, 2017.
[7] ZHANG XL, WANG YN, MA LY, et al.Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway[J]. Acta Pharmacol Sin, 2020, 41(3): 383-393.
[8] QIN Y, PUYANG S, JUAN L, et al.Rho, a fraction from rhodiola crenulate, ameliorates hepatic steatosis in mice models[J]. Front Physiol,2018,9:222.
[9] YKI-JARVINEN H.Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 901-910.
[10] YOUNOSSI ZM, GOLABI P, AVILA LD, et al.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
[11] ROHM TV, MEIER DT, OLEFSKY JM, et al.Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022, 55(1): 31-55.
[12] JAHN D, KIRCHER S, HERMANNS HM, et al.Animal models of NAFLD from a hepatologist’s point of view[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 943-953.
[13] WANG B, CHANDRASEKERA PC, PIPPIN JJ.Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes[J]. Curr Diabetes Rev, 2014, 10(2): 131-145.
[14] SUN G, JACKSON CV, ZIMMERMAN K, et al.The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose[J]. BMC Gastroenterol, 2019, 19(1): 41.
[15] MACHADO MV, MICHELOTTI GA, XIE G, et al.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease[J]. PLoS One, 2015, 10(6): e0132315.
[16] MA Y, LI J, JU Z, et al.Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway[J]. J Ethnopharmacol, 2021, 279: 114320-114329.
[17] LI X, WANG TX, HUANG X, et al.Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity[J]. Liver Int, 2020, 40(6): 1378-1394.
[18] FURMAN BL.Streptozotocin-induced diabetic models in mice and rats[J]. Curr Protoc, 2021, 1(4): e78.
[19] FUJII M, SHIBAZAKI Y, WAKAMATSU K, et al.A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J]. Med Mol Morphol, 2013, 46(3): 141-152.
[20] YAN D, LI SY, WEI YY.Study on establishment of animal model with diabetes complicated fatty liver induced by streptozocin and nicotinamide[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2015, 31(18): 1846-1848.
[21] YAMAMOTO T, YAMAGUCHI H, MIKI H, et al.Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets[J]. Eur J Pharmacol, 2010, 640(1-3): 243-249.
[22] YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
[23] BYRNE CD, TARGHER G.NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64.
[24] AAGHARPOUR A, CAZANAVE SC, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]. J Hepatol, 2016, 65(3): 579-588.
[25] LOU JL, WANG Q, YANG S, et al.Hepatic injury in diabetic KKAY mice[J].Chinese Journal of Cellular and Molecular Immunology(细胞与分子免疫学杂志), 2008(9): 902-903.
[26] ESLAM M, VALENTI L, ROMEO S.Genetics and epigenetics of NAFLD and NASH: clinical impact[J]. J Hepatol, 2018, 68(2): 268-279.
[27] SONG YL, HUANG JK, CONG JL, et al.Establishment of an animal model of diabetic gastroparesis[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(4): 341-345.